HC Wainwright & Co. Reiterates Buy on Anavex Life Sciences, Maintains $40 Price Target

BenzingaNov 4 19:29 · Ratings

Anavex Life Sciences: Buy Rating Driven by Promising Blarcamesine Developments and Market Expansion

TipRanksNov 4 19:15 · Ratings

Anavex Life Sciences Shares Are Trading Higher After the Company Announced New Data From the Phase IIb/III Study Showing That Blarcamesine, Once Daily Orally, Demonstrates Pre-specified Clinical Efficacy Through Upstream SIGMAR1 Activation.

BenzingaNov 1 02:58

12 Health Care Stocks Moving In Thursday's Intraday Session

BenzingaNov 1 00:34

JonesTrading Maintains Anavex Life Sciences(AVXL.US) With Buy Rating, Maintains Target Price $15

Futu NewsOct 31 23:32 · Ratings

Anavex Life Sciences Is Maintained at Buy by EF Hutton

Dow JonesOct 31 21:13 · Ratings